AU5159798A - Branched peptide linkers - Google Patents

Branched peptide linkers

Info

Publication number
AU5159798A
AU5159798A AU51597/98A AU5159798A AU5159798A AU 5159798 A AU5159798 A AU 5159798A AU 51597/98 A AU51597/98 A AU 51597/98A AU 5159798 A AU5159798 A AU 5159798A AU 5159798 A AU5159798 A AU 5159798A
Authority
AU
Australia
Prior art keywords
peptide linkers
branched peptide
branched
linkers
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU51597/98A
Inventor
Gene M. Dubowchik
Raymond A. Firestone
Dalton King
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AU5159798A publication Critical patent/AU5159798A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/641—Branched, dendritic or hypercomb peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU51597/98A 1996-11-05 1997-10-31 Branched peptide linkers Abandoned AU5159798A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3036796P 1996-11-05 1996-11-05
US60030367 1996-11-05
PCT/US1997/019851 WO1998019705A1 (en) 1996-11-05 1997-10-31 Branched peptide linkers

Publications (1)

Publication Number Publication Date
AU5159798A true AU5159798A (en) 1998-05-29

Family

ID=21853889

Family Applications (1)

Application Number Title Priority Date Filing Date
AU51597/98A Abandoned AU5159798A (en) 1996-11-05 1997-10-31 Branched peptide linkers

Country Status (5)

Country Link
EP (1) EP0941120A4 (en)
JP (1) JP2001505194A (en)
AU (1) AU5159798A (en)
CA (1) CA2264610A1 (en)
WO (1) WO1998019705A1 (en)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0961619A4 (en) * 1996-09-27 2001-09-26 Bristol Myers Squibb Co Hydrolyzable prodrugs for delivery of anticancer drugs to metastatic cells
US6331289B1 (en) 1996-10-28 2001-12-18 Nycomed Imaging As Targeted diagnostic/therapeutic agents having more than one different vectors
IL129444A0 (en) 1996-10-28 2000-02-29 Nycomed Imaging As Improvements in or relating to diagnostic/therapeutic agents
US6261537B1 (en) 1996-10-28 2001-07-17 Nycomed Imaging As Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors
WO1999025729A1 (en) * 1997-11-18 1999-05-27 Chugai Seiyaku Kabushiki Kaisha Compounds with antitumor activity
EP1080732A4 (en) * 1998-05-22 2004-08-25 Daiichi Seiyaku Co Drug composites
KR20010090602A (en) 1998-10-30 2001-10-18 스즈키 다다시 DDS Compounds and Method for Assaying the Same
MXPA01008699A (en) * 1999-02-24 2002-06-21 Uab Research Foundation Taxane derivatives for targeted therapy of cancer.
WO2000064486A2 (en) * 1999-04-28 2000-11-02 Vectramed, Inc. Enzymatically activated polymeric drug conjugates
NZ517772A (en) 1999-11-24 2004-03-26 Immunogen Inc Cytotoxic agents comprising taxanes and their therapeutic use
DE10048417A1 (en) * 2000-09-29 2002-04-11 Roche Diagnostics Gmbh Branched linker connections
JP2004528309A (en) 2001-03-23 2004-09-16 ナプロ バイオセラピューティクス，インコーポレイテッド Molecular complex for cancer treatment
DE60235408D1 (en) * 2001-12-17 2010-04-01 Univ Cardiff ENZYMATIC CLEAVAGE REAGENTS FOR SPECIFIC TARGETING OF DISEASES
CN100522955C (en) 2002-08-02 2009-08-05 伊缪诺金公司 Cytotoxic agents containing novel potent taxanes and their therapeutic use
US7390898B2 (en) 2002-08-02 2008-06-24 Immunogen Inc. Cytotoxic agents containing novel potent taxanes and their therapeutic use
AU2003256038A1 (en) * 2002-08-30 2004-03-19 Ramot At Tel Aviv University Ltd. Self-immolative dendrimers releasing many active moieties upon a single activating event
JP2006507322A (en) 2002-11-14 2006-03-02 シンタルガ・ビーブイ Prodrugs constructed as multiple self-detaching release spacers
WO2004081538A2 (en) 2003-03-13 2004-09-23 Irm, Llc Compositions and methods of vinyl oxazolone polymerization
US20040228831A1 (en) * 2003-05-15 2004-11-18 Belinka Benjamin A. Polymeric conjugates for tissue activated drug delivery
EP1651766A2 (en) * 2003-08-05 2006-05-03 Wisconsin Alumni Research Foundation Targeted carrier fusions for delivery of chemotherapeutic agents
SG173313A1 (en) 2005-01-05 2011-08-29 Biogen Idec Inc Cripto binding molecules
KR101129509B1 (en) * 2006-10-03 2012-04-13 알닐람 파마슈티칼스 인코포레이티드 Lipid containing formulations
WO2013012733A1 (en) 2011-07-15 2013-01-24 Biogen Idec Ma Inc. Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
HUE039033T2 (en) 2012-01-10 2018-12-28 Biogen Ma Inc Enhancement of transport of therapeutic molecules across the blood brain barrier
WO2014194030A2 (en) * 2013-05-31 2014-12-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
WO2015095223A2 (en) * 2013-12-16 2015-06-25 Genentech, Inc. Peptidomimetic compounds and antibody-drug conjugates thereof
PE20161394A1 (en) 2013-12-16 2017-01-06 Genentech Inc PEPTIDOMIMETIC COMPOUNDS AND THEIR ANTIBODY-DRUG CONJUGATES
EP3912641A1 (en) 2014-02-17 2021-11-24 Seagen Inc. Hydrophilic drug-linker compounds
WO2015148126A1 (en) 2014-03-12 2015-10-01 Invictus Oncology Pvt. Ltd. Targeted drug delivery through affinity based linkers
KR101628872B1 (en) 2014-05-28 2016-06-09 주식회사 레고켐 바이오사이언스 Compounds comprising self-immolative group
EP3307780A1 (en) 2015-06-15 2018-04-18 Genentech, Inc. Antibodies and immunoconjugates
AU2016359234B2 (en) 2015-11-25 2022-09-08 Legochem Biosciences, Inc. Conjugates comprising peptide groups and methods related thereto
CA3006242A1 (en) 2015-11-25 2017-06-01 Legochem Biosciences, Inc. Conjugates comprising self-immolative groups and methods related thereto
KR20180078329A (en) 2015-11-25 2018-07-09 주식회사 레고켐 바이오사이언스 Antibody-drug conjugates comprising branched linkers and methods for their preparation
AU2018246806B2 (en) 2017-03-29 2022-05-12 Legochem Biosciences, Inc. Pyrrolobenzodiazepine dimer precursor and ligand-linker conjugate compound thereof
IL276546B1 (en) 2018-02-20 2024-04-01 Seagen Inc Hydrophobic auristatin f compounds and conjugates thereof
AU2019266406A1 (en) 2018-05-09 2020-11-26 Legochem Biosciences, Inc. Compositions and methods related to anti-CD19 antibody drug conjugates
KR20210028544A (en) 2019-09-04 2021-03-12 주식회사 레고켐 바이오사이언스 Antibody-drug conjugate comprising antibody binding to antibody against human ROR1 and its use
MX2023001466A (en) 2020-08-03 2023-03-03 Bicycletx Ltd Peptide-based linkers.
CN116348479A (en) 2020-09-30 2023-06-27 豪夫迈·罗氏有限公司 Bacterial pilus protein complex FimGt-DsF stable protein complex for the production of filamentous phage
EP4349373A1 (en) * 2021-06-01 2024-04-10 Ajinomoto Co., Inc. Conjugate of antibody and functional substance or salt of said conjugate, and compound for use in production of said conjugate or salt of said compound

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5084560A (en) * 1986-06-30 1992-01-28 Oncogen Immunoconjugates and methods for their use in tumor therapy
US4975278A (en) * 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5563250A (en) * 1987-12-02 1996-10-08 Neorx Corporation Cleavable conjugates for the delivery and release of agents in native form
US5017693A (en) * 1987-12-02 1991-05-21 Neorx Corporation Methods for introducing a sulfhydryl amino or hydroxyl groups to a compound
IL106992A (en) * 1988-02-11 1994-06-24 Bristol Myers Squibb Co Acylhydrazone derivatives of anthracycline and methods for their preparation
US5252713A (en) * 1988-09-23 1993-10-12 Neorx Corporation Polymeric carriers for non-covalent drug conjugation
US5116944A (en) * 1989-12-29 1992-05-26 Neorx Corporation Conjugates having improved characteristics for in vivo administration
IT1240643B (en) * 1990-05-11 1993-12-17 Mediolanum Farmaceutici Spa BIOLOGICALLY ACTIVE PEPTIDES CONTAINING IN 2-ALCHYL TRIPTOFANE CHAIN
US5137877B1 (en) * 1990-05-14 1996-01-30 Bristol Myers Squibb Co Bifunctional linking compounds conjugates and methods for their production
EP0578774B1 (en) * 1991-04-05 1998-07-29 The Board Of Regents Of The University Of Washington Monoclonal antibodies to stem cell factor receptors
US5622929A (en) * 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5443953A (en) * 1993-12-08 1995-08-22 Immunomedics, Inc. Preparation and use of immunoconjugates

Also Published As

Publication number Publication date
CA2264610A1 (en) 1998-05-14
EP0941120A4 (en) 2004-08-18
EP0941120A1 (en) 1999-09-15
WO1998019705A1 (en) 1998-05-14
JP2001505194A (en) 2001-04-17

Similar Documents

Publication Publication Date Title
AU5159798A (en) Branched peptide linkers
AU3049397A (en) Cyclosporin-containing pharmaceutical composition
AU4922497A (en) Interleukin-18-receptor proteins
AU2972097A (en) Peptide derivatives
AU6721696A (en) Cd44-like protein
AU1803597A (en) Peptide derivatives
AU4427296A (en) Novel peptide
AU4394396A (en) Modified peptides
AU2131195A (en) Prophenins - antibiotic peptides
AU4967397A (en) Water-soluble peptides
AU5061698A (en) Peptide derivatives
AU1999999A (en) Contryphan peptides
AU5764898A (en) Multiple branch peptide constructions
AUPM489194A0 (en) Peptides
AU5161296A (en) Anti-haemorrhagic peptides
AUPO324096A0 (en) Linker peptide
AU9109098A (en) Hypusine peptides
AU2233497A (en) Peptide derivatives
AUPO216596A0 (en) Novel peptides
AUPO330996A0 (en) Novel peptides
AUPO383096A0 (en) Novel peptides
AUPO434796A0 (en) Novel peptides
AUPO061096A0 (en) Novel peptides
AUPO268096A0 (en) Cytotoxic peptides
AUPO265996A0 (en) Cytotoxic peptides